銆€銆€鏍规嵁銆�鍏借嵂绠$悊鏉′緥銆嬪拰銆婂吔鑽敞鍐屽姙娉曘€嬭瀹氾紝缁忓鏌ワ紝鎵瑰噯娉曞浗缁村厠鏈夐檺鍏徃绛�7瀹跺叕鍙哥敓浜х殑娉ㄥ皠鐢�鐩愰吀鏇挎潵浠栨槑鐩愰吀鍞戞媺瑗挎钞绛�8绉嶅吔鑽骇鍝佸湪鎴戝浗鍐嶆敞鍐岋紝鏍稿彂銆�杩涘彛鍏借嵂娉ㄥ唽璇佷功銆嬶紝骞跺彂甯冨伐鑹鸿绋嬪拰淇鍚庣殑璐ㄩ噺鏍囧噯銆佽鏄庝功鍜�鏍囩锛岃嚜鍙戝竷涔嬫棩璧锋墽琛屻€傛鍓嶅彂甯冪殑涓婅堪8绉嶅吔鑽川閲忔爣鍑嗐€佽鏄庝功鍜屾爣绛惧悓鏃跺簾姝€€�
銆€銆€鎵瑰噯缇庡浗娲炬柉鎭╁埗鑽湁闄愯矗浠诲叕鍙哥敓浜х殑姘熼浄鎷夌撼婊村墏鍦ㄦ垜鍥藉彉鏇存敞鍐岋紝璐ㄩ噺鏍囧噯銆佽鏄庝功鍜屾爣绛惧叾浠栧唴瀹规寜鐓у啘涓氬啘鏉戦儴鍏憡绗�686鍙峰悓鍝佺鎵ц銆傛壒鍑嗗媰鏋楁牸娈锋牸缈板姩鐗╀繚鍋ユ湁闄愬叕鍙告硶鍥藉悙椴佸吂鐢熶骇鍘傜敓浜х殑澶嶆柟闈炴臣缃楀凹鍚″柟閰淮鍓傚湪鎴戝浗鍙樻洿娉ㄥ唽锛岃川閲忔爣鍑嗗叾浠栧唴瀹规寜鐓у啘涓氬啘鏉戦儴鍏憡绗�782鍙峰悓鍝佺鎵ц锛岃鏄庝功鍜屾爣绛惧叾浠栧唴瀹规寜鐓у啘涓氬啘鏉戦儴鍏憡绗�469鍙峰悓鍝佺鎵ц銆�
銆€銆€鐗规鍏憡銆�
銆€銆€闄勪欢锛� 1.杩涘彛鍏借嵂娉ㄥ唽鐩綍
銆€銆€2.璐ㄩ噺鏍囧噯
銆€銆€3.宸ヨ壓瑙勭▼
銆€銆€4.璇存槑涔﹀拰鏍囩
銆€銆€鍐滀笟鍐滄潙閮�
銆€銆€2024骞�10鏈�29鏃�
闄勪欢1
杩涘彛鍏借嵂娉ㄥ唽鐩綍
鍏借嵂鍚嶇О
|
鐢熶骇鍘�
鍚嶇О
|
鍥� 鍒�
|
杩涘彛鍏借嵂
娉ㄥ唽
璇佷功鍙�
|
鏈夋晥鏈熼檺
|
澶囨敞
|
娉ㄥ皠鐢ㄧ洂閰告浛鏉ヤ粬鏄庣洂閰稿攽鎷夎タ娉�
锛堟浛鏉ヤ粬鏄�125mg+鍞戞媺瑗挎钞125mg锛�
Tiletamine Hydrochloride and Zolazepam Hydrochloride for Injection
|
娉曞浗缁村厠鏈夐檺鍏徃
VIRBAC
|
娉曞浗
|
锛�2020锛�
澶栧吔鑽瘉瀛�
06鍙�
|
2024.10.29
—
2029.10.28
|
鍐嶆敞鍐�
锛堣繘鍙e吔鑽敞鍐岃瘉涔﹀彿涓嶅彉锛�
|
娉ㄥ皠鐢ㄧ洂閰告浛鏉ヤ粬鏄庣洂閰稿攽鎷夎タ娉�
锛堟浛鏉ヤ粬鏄�250mg+鍞戞媺瑗挎钞250mg锛�
Tiletamine Hydrochloride and Zolazepam Hydrochloride for Injection
|
锛�2020锛�
澶栧吔鑽瘉瀛�
07鍙�
|
2024.10.29
—
2029.10.28
|
鍐嶆敞鍐�
锛堣繘鍙e吔鑽敞鍐岃瘉涔﹀彿涓嶅彉锛�
|
||
澶嶆柟瀛i摰鐩愭垔浜岄啗婧舵恫
锛�1000ml锛氱兎鍩轰簩鐢插熀鑻勫熀姘寲閾�170.6g+浜岀櫢鍩轰簩鐢插熀姘寲閾�78.0g+鎴婁簩閱�107.25g锛�
Compound Quaternary Ammonium Salts and Glutaral Solution
|
涓栧痉鏉ユ湁闄愬叕鍙�
CID LINES NV/SA
|
姣斿埄鏃�
|
锛�2019锛�
澶栧吔鑽瘉瀛�
69鍙�
|
2024.10.29
—
2029.10.28
|
鍐嶆敞鍐�
锛堣繘鍙e吔鑽敞鍐岃瘉涔﹀彿涓嶅彉锛�
|
鐘粏灏忕梾姣掔梾娲荤柅鑻楋紙NL-35-D鏍級Parvovirus Vaccine锛孡ive锛圫train NL-35-D锛�
|
纭曡吘鍏徃缇庡浗鏋楄偗鍘�
Zoetis Inc., Lincoln, USA
|
缇庡浗
|
锛�2020锛�
澶栧吔鑽瘉瀛�
28鍙�
|
2024.10.29
—
2029.10.28
|
鍐嶆敞鍐�
锛堣繘鍙e吔鑽敞鍐岃瘉涔﹀彿涓嶅彉锛�
|
楦¢┈绔嬪厠姘忕梾I鍨嬨€両II鍨嬩簩浠锋椿鐤嫍锛圕VI988鏍�+FC-126鏍級
Marek’s Disease Vaccine Serotypes 1&3, Live Virus
|
纭曡吘鍏徃缇庡浗鏌ョ悊鏂牎鐢熶骇鍘�
Zoetis Inc.,Charles City,USA
|
缇庡浗
|
锛�2020锛�
澶栧吔鑽瘉瀛�
27鍙�
|
2024.10.29
—
2029.10.28
|
鍐嶆敞鍐�
锛堣繘鍙e吔鑽敞鍐岃瘉涔﹀彿涓嶅彉锛�
|
鍦熼湁绱犳敞灏勬恫
锛�100ml鈭�20g锛塐xytetracycline Injection
|
TriRx Shawnee璐d换鏈夐檺鍏徃TriRx Shawnee, LLC
|
缇庡浗
|
锛�2020锛�
澶栧吔鑽瘉瀛�
01鍙�
|
2024.10.29
—
2029.10.28
|
鍐嶆敞鍐�
锛堣繘鍙e吔鑽敞鍐岃瘉涔﹀彿涓嶅彉锛�
鍙樻洿娉ㄥ唽锛氬師鏂欒嵂鏉ユ簮鍒犲噺鍙樻洿涓鸿丹宄板埗鑽偂浠芥湁闄愬叕鍙�
|
鍦熼湁绱犳敞灏勬恫
锛�250ml鈭�50g锛�
Oxytetracycline Injection
|
锛�2020锛�
澶栧吔鑽瘉瀛�
02鍙�
|
||||
鍦熼湁绱犳敞灏勬恫
锛�500ml鈭�100g锛�
Oxytetracycline Injection
|
锛�2020锛�
澶栧吔鑽瘉瀛�
03鍙�
|
||||
纰樻贩鍚堟憾娑�
锛�0.25%锛�
Iodine Mixed Solution
|
鍒╂媺浼怤.V.鍏徃
DeLaval N.V.
|
姣斿埄鏃�
|
锛�2019锛�
澶栧吔鑽瘉瀛�
107鍙�
|
2024.10.29
—
2029.10.28
|
鍐嶆敞鍐�
锛堣繘鍙e吔鑽敞鍐岃瘉涔﹀彿涓嶅彉锛�
|
纰樼敇娌规贩鍚堟憾娑�
锛�0.75%锛坓/g锛夛級
Iodine and Glycerol Mixed Solution
|
鍒╂媺浼怤.V.鍏徃
DeLaval N.V.
|
姣斿埄鏃�
|
锛�2019锛�
澶栧吔鑽瘉瀛�
78鍙�
|
2024.10.29
—
2029.10.28
|
鍐嶆敞鍐�
锛堣繘鍙e吔鑽敞鍐岃瘉涔﹀彿涓嶅彉锛�
|
鐚敮鍘熶綋鑲虹値鐏椿鐤嫍锛圝鏍級
Swine Mycoplasma Hyopneumoniae Vaccine锛孖nactivated锛圫train J锛�
|
瑗跨彮鐗欐捣鍗氳幈鐢熺墿澶ц嵂鍘侺aboratorios HIPRA, S.A.
|
瑗跨彮鐗�
|
锛�2020锛�
澶栧吔鑽瘉瀛�
05鍙�
|
2024.10.29
—
2029.10.28
|
鍐嶆敞鍐�
锛堣繘鍙e吔鑽敞鍐岃瘉涔﹀彿涓嶅彉锛�
|
姘熼浄鎷夌撼婊村墏
锛�0.4 ml鈭舵盁闆锋媺绾�0.1125g锛�
Fluralaner Spot-On Solution
|
缇庡浗娲炬柉鎭╁埗鑽湁闄愯矗浠诲叕鍙�
Patheon Manufacturing Services LLC
|
缇庡浗
|
锛�2023锛�
澶栧吔鑽瘉瀛�
14鍙�
|
2023.07.11
—
2028.07.10
|
鍙樻洿娉ㄥ唽锛氫慨鏀瑰吔鑽敞鍐屾爣鍑�
|
姘熼浄鎷夌撼婊村墏
锛�0.89ml鈭舵盁闆锋媺绾�0.25g锛�
Fluralaner Spot-On Solution
|
缇庡浗娲炬柉鎭╁埗鑽湁闄愯矗浠诲叕鍙�
Patheon Manufacturing Services LLC
|
缇庡浗
|
锛�2023锛�
澶栧吔鑽瘉瀛�
15鍙�
|
2023.07.11
—
2028.07.10
|
鍙樻洿娉ㄥ唽锛氫竴銆佹湁鏁堟湡鐢�24涓湀鍙樻洿涓�36涓湀锛涗簩銆佷慨鏀瑰吔鑽敞鍐屾爣鍑�
|
姘熼浄鎷夌撼婊村墏
锛�1.79ml鈭舵盁闆锋媺绾�0.5g锛�
Fluralaner Spot-On Solution
|
锛�2023锛�
澶栧吔鑽瘉瀛�
16鍙�
|
||||
姘熼浄鎷夌撼婊村墏
锛�3.57ml鈭舵盁闆锋媺绾�1.0g锛�
Fluralaner Spot-On Solution
|
锛�2023锛�
澶栧吔鑽瘉瀛�
17鍙�
|
||||
姘熼浄鎷夌撼婊村墏
锛�5.0ml鈭舵盁闆锋媺绾�1.4g锛�
Fluralaner Spot-On Solution
|
锛�2023锛�
澶栧吔鑽瘉瀛�
18鍙�
|
||||
澶嶆柟闈炴臣缃楀凹鍚″柟閰淮鍓�
锛�0.9ml/绠★級
Compound Fipronil and Praziquantel Spot-On Solution
|
鍕冩灄鏍兼鏍肩堪鍔ㄧ墿淇濆仴鏈夐檺鍏徃娉曞浗鍚愰瞾鍏圭敓浜у巶Boehringer Ingelheim Animal Health France
|
娉曞浗
|
锛�2021锛�
澶栧吔鑽瘉瀛�
55鍙�
|
2021.09.06
—
2026.09.05
|
鍙樻洿娉ㄥ唽锛氭湁鏁堟湡鐢�24涓湀鍙樻洿涓�36涓湀
|
銆€銆€闄勪欢锛�
銆€銆€
璇存槑涔﹀拰鏍囩.pdf
